Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Total Liabilities (2020 - 2025)

Gain Therapeutics has reported Total Liabilities over the past 6 years, most recently at $5.1 million for Q3 2025.

  • Quarterly results put Total Liabilities at $5.1 million for Q3 2025, down 7.22% from a year ago — trailing twelve months through Sep 2025 was $5.1 million (down 7.22% YoY), and the annual figure for FY2024 was $4.8 million, down 20.67%.
  • Total Liabilities for Q3 2025 was $5.1 million at Gain Therapeutics, down from $6.1 million in the prior quarter.
  • Over the last five years, Total Liabilities for GANX hit a ceiling of $7.4 million in Q2 2024 and a floor of $3.6 million in Q1 2021.
  • Median Total Liabilities over the past 5 years was $5.7 million (2022), compared with a mean of $5.5 million.
  • Biggest five-year swings in Total Liabilities: soared 5181.04% in 2021 and later fell 20.67% in 2024.
  • Gain Therapeutics' Total Liabilities stood at $4.2 million in 2021, then increased by 25.25% to $5.2 million in 2022, then rose by 15.54% to $6.0 million in 2023, then fell by 20.67% to $4.8 million in 2024, then grew by 5.81% to $5.1 million in 2025.
  • The last three reported values for Total Liabilities were $5.1 million (Q3 2025), $6.1 million (Q2 2025), and $5.8 million (Q1 2025) per Business Quant data.